METTL3 promotes an immunosuppressive microenvironment in bladder cancer via m6A-dependent CXCL5/CCL5 regulation
Journal for ImmunoTherapy of Cancer · 2025-04 · 13 (4) · e011108
DOI: 10.1136/jitc-2024-011108 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 15.04.2025. Verfasst von Yonghua Tong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Tumor Microenvironment, Methyltransferases, Chemokine CCL5. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Young Elite Scientists Sponsorship Program by CAST, National Natural Science Foundation of China, Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
Background
Bladder cancer (BLCA) is a challenging malignancy with a poor prognosis, particularly in muscle-invasive cases. Despite recent advancements in immunotherapy, response rates remain suboptimal. This study investigates the role of METTL3, an m6A RNA methylation “writer,” in regulating the immune microenvironment of BLCA.
Methods
Through bioinformatics analysis, we identified METTL3 as being associated with the formation of an immunosuppressive microenvironment in BLCA and poor response to immunotherapy. Subsequently, we silenced METTL3 expression in BLCA cells using short hairpin RNA (shRNA) or inhibited its function with STM2457. The effectiveness of these interventions in remodeling the BLCA tumor microenvironment (TME) was confirmed through animal experiments and flow cytometry. Mechanistically, RNA sequencing and methylated RNA immunoprecipitation (MeRIP) sequencing revealed the molecular pathways by which METTL3 regulates the TME. This was further validated using in vitro cell co-culture, immunoprecipitation, ELISA, and RNA degradation assays. The synergistic effect of METTL3 with anti-Programmed Cell Death Protein 1 (PD-1) treatment in BLCA was confirmed in both orthotopic and ectopic BLCA animal models.
Results
METTL3 was found to increase CXCL5 levels and suppress CCL5 expression in an m6A-dependent manner, leading to increased recruitment of myeloid-derived suppressor cells (MDSCs) and reduced infiltration of CD8+T cells. Silencing METTL3 or inhibiting its function restored immune cell balance and significantly enhanced the efficacy of anti-PD-1 therapy. Clinically, METTL3 overexpression correlated with poor complete response rate to immune checkpoint inhibitors (ICIs) therapy, associated with an immunosuppressive microenvironment characterized by elevated MDSC levels and reduced CD8+T cell infiltration.
Conclusions
These findings highlight METTL3 as a key regulator of the immune microenvironment in BLCA and a promising therapeutic target to improve immunotherapy outcomes. Targeting METTL3 could potentially enhance the efficacy of ICIs in patients with BLCA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Huazhong University of Science and Technology, Wuhan, China.
- Department of Urology, Huazhong University of Science and Technology, Wuhan, China tangsk1990@163.com liangxy1@sysucc.org.cn zhwang_hust@hotmail.com.
- State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, Guangdong, China tangsk1990@163.com liangxy1@sysucc.org.cn zhwang_hust@hotmail.com.
- Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Förderung
- Young Elite Scientists Sponsorship Program by CAST
- National Natural Science Foundation of China
- Natural Science Foundation of Hubei Province
Zitieren
APA
Tong, Y., Chen, Z., Wu, J., Huang, Q., He, Y., Shang, H., Xia, D., Peng, E., Wang, Z., Liang, X., & Tang, K. (2025). METTL3 promotes an immunosuppressive microenvironment in bladder cancer via m6A-dependent CXCL5/CCL5 regulation. Journal for ImmunoTherapy of Cancer, 13(4), e011108. https://doi.org/10.1136/jitc-2024-011108
Vancouver
Tong Y, Chen Z, Wu J, Huang Q, He Y, Shang H, et al. METTL3 promotes an immunosuppressive microenvironment in bladder cancer via m6A-dependent CXCL5/CCL5 regulation. Journal for ImmunoTherapy of Cancer. 2025;13(4):e011108. doi:10.1136/jitc-2024-011108
BibTeX
@article{Tong2025,
author = {Tong, Yonghua and Chen, Zhiqiang and Wu, Jian and Huang, Qiu and He, Yu and Shang, Haojie and Xia, Ding and Peng, Ejun and Wang, Zhihua and Liang, Xiaoyu and Tang, Kun},
title = {METTL3 promotes an immunosuppressive microenvironment in bladder cancer via m6A-dependent CXCL5/CCL5 regulation},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {4},
pages = {e011108},
doi = {10.1136/jitc-2024-011108}
}
EUVIMED